Literature DB >> 31872385

miR-300 mitigates cancer-induced bone pain through targeting HMGB1 in rat models.

Chenglong Liu1,2, Jianping Yang3, Haihua Liu4, Tian Xia2, Fei Zhang2.   

Abstract

BACKGROUND: Cancer-induced bone pain (CIBP) is the pain caused by bone metastasis from malignant tumors, and the largest source of pain for cancer patients. miR-300 is an important miRNA in cancer. It has been shown that miR-300 regulates tumorigenesis of various tumors.
OBJECTIVE: This study aims to investigate the role of miR-300 in CIBP and its underlying molecular mechanisms in vitro and in vivo.
METHODS: We constructed CIBP model in rats and investigated the mechanism through which miR-300 affects CIBP. We first examined expression level of miR-300 in CIBP rats and then tested the effect of its overexpression. Next, we identified the target of miR-300 using TargetScan analysis and double luciferase assay. Finally, we studied genetic interactions between miR-300 and its target and their roles in CIBP.
RESULTS: We found that miR-300 was downregulated in CIBP rats. Overexpression of miR-300 significantly attenuated cancer-induced neuropathic pain (p < 0.01). Furthermore, TargetScan analysis and double luciferase assay show High Mobility Group Box 1 (HMGB1) is a target of miR-300. Notably, HMGB1 is overexpressed in CIBP rats, while up-regulation of miR-300 significantly suppresses expression of HMGB1 (p < 0.01). Moreover, knockdown of HMGB1 by siRNA significantly relieves cancer-induced neuropathic pain in rats (p < 0.01). On the other hand, HMGB1 overexpression partially blocked the effect of miR-300 on cancer-induced nerve pain.
CONCLUSION: miR-300 relieves cancer-induced neuropathic pain by inhibiting HMGB1 expression. These results may be beneficial for the treatment of CIBP in clinical practice.

Entities:  

Keywords:  Cancer-induced bone; HMGB1; Neuropathic pain; Pain; miR-300

Mesh:

Substances:

Year:  2019        PMID: 31872385     DOI: 10.1007/s13258-019-00904-9

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  43 in total

1.  Ethyl pyruvate suppresses the growth, invasion and migration and induces the apoptosis of non‑small cell lung cancer cells via the HMGB1/RAGE axis and the NF‑κB/STAT3 pathway.

Authors:  Qiongqiong Liu; Yansong Huo; Hong Zheng; Jing Zhao; Li Jia; Peiguo Wang
Journal:  Oncol Rep       Date:  2019-05-30       Impact factor: 3.906

Review 2.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

Authors:  R E Coleman
Journal:  Cancer Treat Rev       Date:  2001-06       Impact factor: 12.111

3.  Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein.

Authors:  Le-Xing Yu; Lei Yan; Wen Yang; Fu-Quan Wu; Yan Ling; Shu-Zhen Chen; Liang Tang; Ye-Xiong Tan; Dan Cao; Meng-Chao Wu; He-Xin Yan; Hong-Yang Wang
Journal:  Nat Commun       Date:  2014-10-28       Impact factor: 14.919

4.  Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain.

Authors:  Wei Tong; Wei Wang; Jing Huang; Ning Ren; Sheng-Xi Wu; Yong-Qi Li
Journal:  Biochem Biophys Res Commun       Date:  2010-04-23       Impact factor: 3.575

5.  The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents.

Authors:  Chengcheng Christine Zhang; Georg Gdynia; Volker Ehemann; Wilfried Roth
Journal:  Int J Oncol       Date:  2014-12-01       Impact factor: 5.650

6.  MiR-300 regulate the malignancy of breast cancer by targeting p53.

Authors:  Xiao-Heng Xu; Da-Wei Li; Hui Feng; Hong-Mei Chen; Yan-Qiu Song
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 7.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

8.  Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.

Authors:  Venita DePuy; Kevin J Anstrom; Liana D Castel; Kevin A Schulman; Kevin P Weinfurt; Fred Saad
Journal:  Support Care Cancer       Date:  2007-07       Impact factor: 3.359

9.  Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain.

Authors:  Jian Zhang; Luping Wang; Hushan Wang; Zhenbo Su; Xiaochuan Pang
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

Review 10.  Use of Animal Models in Understanding Cancer-induced Bone Pain.

Authors:  Lauren M Slosky; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Cancer Growth Metastasis       Date:  2015-08-23
View more
  4 in total

1.  Knockdown of PAR2 alleviates cancer-induced bone pain by inhibiting the activation of astrocytes and the ERK pathway.

Authors:  Yiting Tang; Yupeng Chen; Mingzhu Yang; Qiuhui Zheng; Yaoyuan Li; Yanju Bao
Journal:  BMC Musculoskelet Disord       Date:  2022-05-30       Impact factor: 2.562

2.  Platelet-rich plasma improves chronic inflammatory pain by inhibiting PKM2-mediated aerobic glycolysis in astrocytes.

Authors:  Xiang Wei; Xiao-Hong Jin; Xiao-Wen Meng; Jie Hua; Fu-Hai Ji; Li-Na Wang; Jian-Ping Yang
Journal:  Ann Transl Med       Date:  2020-11

3.  microRNA-Based Network and Pathway Analysis for Neuropathic Pain in Rodent Models.

Authors:  Yi-Li Zheng; Xuan Su; Yu-Meng Chen; Jia-Bao Guo; Ge Song; Zheng Yang; Pei-Jie Chen; Xue-Qiang Wang
Journal:  Front Mol Biosci       Date:  2022-01-13

4.  The impacts of exosomes on bone metastatic progression and their potential clinical utility.

Authors:  Jenna Ollodart; Kelly F Contino; Gagan Deep; Yusuke Shiozawa
Journal:  Bone Rep       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.